By Josh White
Date: Wednesday 12 Apr 2023
(Sharecast News) - Drug discovery and development company ImmuPharma announced positive progress in its late-stage P140 clinical programme on Tuesday, for patients with chronic idiopathic demyelinating polyneuropathy (CIDP), a rare neurological disease with high medical need.
By Josh White
Date: Friday 11 Nov 2022
(Sharecast News) - Drug discovery and development specialist ImmuPharma updated the market on a recent meeting in Atlanta with its United States partner Avion Pharmaceuticals on Friday, for strategic discussions around its 'Lupuzor' clinical programme.
By Josh White
Date: Wednesday 14 Sep 2022
(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Wednesday that its US partner for 'Lupuzor', Avion Pharmaceuticals, has received a written response from the Food and Drug Administration (FDA).
Currency | UK Pounds |
Share Price | 2.14p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 3.42 |
52 Week Low | 0.85 |
Volume | 604,698 |
Shares Issued | 416.44m |
Market Cap | £8.91m |
RiskGrade | 328 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
15:55 | 20,000 @ 2.14p |
15:13 | 60,201 @ 2.14p |
13:57 | 25,000 @ 2.14p |
13:54 | 50,000 @ 2.14p |
12:33 | 603 @ 2.20p |
You are here: research